Biotronik's ICD home monitoring cuts inappropriate shocks in half

December 18, 2012 by MassDevice staff

Biotronik's ECOST study shows that the device maker's ICD home monitoring reduces inappropriate shocks by half and helps extend device battery life.

Biotronik logo

Cardiovascular medical device maker Biotronik unveiled clinical results from its Effectiveness & Cost of ICD Follow-Up Schedule with Telecardiology trial, which showed that the company's home monitoring system reduced inappropriate implantable cardioverter defibrillator shocks by 52% while extending the device's battery-life.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.